ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Nuvelo revises Archemix deal

August 7, 2006 | APPEARED IN VOLUME 84, ISSUE 32

Archemix and Nuvelo have expanded their anticoagulation drug development pact. Under the new agreement, Archemix will discover short-acting aptamers targeting the coagulation cascade, and Nuvelo will spearhead their development and commercialization. Nuvelo will make an up-front payment of $4 million, will fund Archemix' research in short-acting aptamers for the next three years, and may invest up to $10 million in Archemix when it goes public. The companies had previously collaborated on Archemix' thrombin inhibitor ARC183, which was dropped from clinical development due to low potency.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment